1,721,048 research outputs found
Going Beyond Counting First Authors in Author Co-citation Analysis
Get PDFThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Get PDF“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Get PDFWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Chromosome 20q genes in the pathogenesis of colorectal cancer
Get PDFMeijer, G.A. [Promotor]Carvalho, B. [Copromotor]Fijneman, R.J.A. [Copromotor
Molecular Biomarkers to Guide Personalized Treatment in Colorectal Cancer
Get PDFColorectal cancer (CRC) remains a significant health issue, with 13,000 new diagnoses annually in the Netherlands. Two promising advancements in molecular diagnostics could improve personalized treatment: circulating tumor DNA (ctDNA) and NTRK gene fusions. CtDNA serves as a biomarker for minimal residual disease (MRD) and therefore disease recurrence and could help tailor adjuvant treatment post-surgery. However, the prognostic value of ctDNA before surgery remains uncertain according to a systematic review of 29 studies. Investigation into ctDNA post-surgery indicated its potential in detecting MRD. A comparative study demonstrated that a tumor-informed ctDNA approach is superior in sensitivity and specificity compared to plasma-only or white blood cells-informed methods. Notably, patients with detectable ctDNA post-surgery had significantly worse recurrence-free and overall survival rates, highlighting ctDNA’s role as a powerful prognostic tool. The MEDOCC-CrEATE trial is an innovative intervention study designed to evaluate whether ctDNA-guided adjuvant chemotherapy can reduce recurrence rates in stage II colon cancer patients. This trial employs the Trials within Cohorts (TwiCs) design, where eligible patients are pre-surgery participants in the PLCRC study and randomized post-surgery. Patients with detectable ctDNA receive additional chemotherapy, aiming to determine the feasibility and efficacy of ctDNA-guided treatment. If successful, this approach could significantly improve patient outcomes by refining adjuvant therapy decisions. NTRK gene fusions, though rare in metastatic CRC (mCRC), represent another area of promising development. These fusions are more prevalent in tumors with deficient DNA repair genes (dMMR). TRK inhibitors like larotrectinib and entrectinib, approved for solid tumors with NTRK fusions, have shown remarkable efficacy, but their clinical benefits compared to standard therapies remain unclear due to the low prevalence of these fusions. Research involving 268 patients with MSI-H/dMMR mCRC revealed a 3.4% prevalence of NTRK fusions, with higher rates in specific subgroups. Tumors with NTRK fusions were often BRAF and RAS wild-type and showed hypermethylation of the MLH1 promoter. Patients with these genetic profiles responded poorly to chemotherapy and anti-EGFR therapy but exhibited prolonged survival with PD-(L)1 inhibitors. This suggests that immunotherapy should be the first-line treatment for MSI-H/dMMR mCRC, regardless of NTRK fusion status, with TRK inhibitors considered as second-line options. Screening for NTRK fusions is recommended using immunohistochemistry (IHC) followed by RNA-based next-generation sequencing (NGS) for confirmation. Alternative assays, such as FFPE Targeted Locus Capture (FFPE-TLC) and the Idylla GeneFusion test, also show high sensitivity and specificity, making them suitable for confirming NTRK fusions post-IHC screening. FISH, however, is not recommended due to limited sensitivity and robustness. These advancements underscore the importance of integrating molecular diagnostics into clinical practice to enhance the precision of colorectal cancer treatment, potentially improving prognosis and patient quality of life
Dispelling the Myths Behind First-author Citation Counts
Get PDFWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
Multi-omics data integration towards biomarkers for colorectal adenoma-to-carcinoma progression
No full textColorectal cancer is a major health concern worldwide. However, colorectal cancer has a high cure rate when detected in its early stages, which is why a population-wide screening program for this disease has been introduced in (a.o.) the Netherlands. Colorectal cancer develops from an adenoma, which is a non-invasive precursor of colorectal cancer. Removal of adenomas is an effective strategy to reduce colorectal cancer mortality rates. However, as only a minority of adenomas progress to cancer, such strategies may lead to overtreatment. High-risk adenomas, defined by specific molecular aberrations, have an increased risk of progressing to cancer. In this thesis, we extensively applied molecular (DNA, RNA, protein) profiling technologies followed by data integration to further characterize high-risk adenomas. We have shown that on molecular level high-risk adenomas in many aspects resemble cancers and express the same biomarkers, which are not expressed by healthy colon or adenomas with lower risk of progression. These biomarkers have promising potential to distinguish individuals with high-risk adenomas and colorectal cancers from healthy individuals and the ones with adenomas with lower risk of progressing, which in the future may be used to improve colorectal cancer screening programs
- …
